Compare Novavax Inc (NVAX) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Novavax Inc trades at $7.88 (market cap $1.31B), while First Trust NASDAQ 100 Technology Index Fund trades at $320. The key difference: First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | QTEC | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $11.19 | $335.74 |
52-Week Low | $6.22 | $207.03 |
Enterprise Value | $889.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
QTEC trades at $320.61, up 1.51% today, with a bullish technical signal driven by strong moving average alignment. The ETF, tracking NASDAQ-100 technology stocks, lacks disclosed fundamental ratios but benefits from broad tech sector exposure. Recent news highlights its role in technology equity access, with a dividend scheduled for June 2026.
Outlook remains tied to technology sector performance, offering growth potential amid innovation trends. Risks include market volatility and sector concentration. Analyst sentiment is positive, but investors should weigh tech cyclicality against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
